ClinicalTrials.gg
Not yet recruitingNCT07159685Updated Sep 8, 2025

Sex-Based Differences of LA: Impact on AF Ablation.

An observational study in Atrial Fibrillation (AF), sponsored by Centro Medico Teknon. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Centro Medico Teknon · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
700
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Atrial Fibrillation with a site in Spain — 53 open to participants now, 76 under way, 3 of them phase 3. Atrial Fibrillation · Spain.

Planned enrollment
35th of 85
700 · median 500
Started
2026
with 9 others
Observational
85 of 247
15 open now
Primary completion
2026-04
later than 27 of 75 live
Registered
228th of 247
by date
Lead sponsor
6 of 247
Centro Medico Teknon

Among the 247 studies in Atrial Fibrillation with a site in Spain, this one is the 35th largest by planned enrollment of the 85 observational ones that give a count, is one of 10 that started in 2026, is one of 85 observational ones, reaches primary completion later than 27 of the 75 other live ones, and was the 228th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

53 of the 247 studies in Atrial Fibrillation with a site in Spain are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Atrial Fibrillation with a site in Spain, or all of them as a file.
02

Study summary

The aim of the study is to assess sex-related differences in patients who underwent a first ablation procedure for paroxysmal or persistent AF, guided by the personalized ablation strategy of the BY-LAWT protocol. Specifically, to compare anatomical characteristics, procedural parameters, and clinical outcomes between sexes.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive patients who underwent a first ablation procedure for paroxysmal or persistent atrial fibrillation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who underwent a first ablation procedure for atrial fibrillation (paroxysmal or persistent).
  • Availability of an adequate pre-procedural cardiac CT scan for LAWT, LAV and inFAT analysis.
  • Availability of complete procedural data, including ablation index (AI) values recorded using the SmartTouch catheter (Biosense Webster).
  • Availability of 12-month follow-up data for efficacy and safety endpoint evaluation.
  • Ablation performed according to the by-LAWT protocol

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years.
  • Previous cardiac ablation (including AF ablation or other arrhythmias).
  • Incomplete data regarding procedural parameters, or follow-up.
  • Poor quality pre-procedural cardiac MDCT
  • Ablation not performed according to the BY-LAWT protocol.
  • Structural heart disease (e.g., dilated cardiomyopathy, valvular heart disease with surgical indication) that could substantially influence atrial dimensions or ablation response.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
700 participants (estimated)
Patient registry
No

Groups and cohorts

  • patients who underwent a first ablation procedure for paroxysmal or persistent atrial fibrillation

    patients who underwent a first ablation procedure for paroxysmal or persistent atrial fibrillation

    Procedure: Atrial fibrillation ablation

Interventions

  • ProcedureAtrial fibrillation ablation

    Atrial fibrillation ablation with RF, guided by navigation system

06

What researchers measure

Primary outcomes

  1. Efficacy in AF freedom

    The primary efficacy endpoint will be freedom from any atrial arrhythmia (AF, atrial tachycardia \[AT\], or atrial flutter \[AFL\]) at the 12-month follow-up. The following definitions apply

    Time frame: from the procedure to 12 months later

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Apr 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Sep 8, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Apr 30, 2026
CompletionEst.
May 30, 2026
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07159685
Lead sponsor
Centro Medico Teknon
Responsible party
Antonio Berruezo, MD, PhD (Chief of Electrophysiology Unit, Centro Medico Teknon) — Principal investigator
First posted
Sep 8, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Apr 30, 2026 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Sep 8, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion